After more than a decade of relentless pursuit, PTC Therapeutics' decision to withdraw its application for Translarna marks a watershed moment for the company and the broader biopharmaceutical landscape for rare diseases. This conclusion to a protracted regulatory saga with the U.S. Food and
The rapid integration of sophisticated artificial intelligence into daily life now extends into one of its most personal and critical domains, with direct-to-consumer health applications promising a new era of accessible medical guidance. The proliferation of artificial intelligence represents a
The once-fragmented landscape of American health data is rapidly coalescing into a unified ecosystem, with the federal government's interoperability framework serving as its powerful gravitational center. A historic milestone announced at the ASTP/ONC 2026 Annual Meeting confirms that the
The once-predictable landscape of American healthcare regulation has shattered into a mosaic of state-level mandates, leaving a national industry to navigate a chaotic and increasingly treacherous compliance environment. A prolonged federal stalemate on critical issues, from drug pricing to supply
Millions of low-income Americans are on the verge of a precarious new reality where maintaining essential health insurance is contingent not on a willingness to work, but on navigating the often-insurmountable barriers of personal illness and family caregiving. This policy shift represents a
The road for patients with advanced hepatocellular carcinoma often narrows dramatically after initial treatments falter, leaving few effective options and a stark prognosis for those who see their disease progress. While the advent of immunotherapy has revolutionized first-line care, a significant
